vDreaming

We May Dream

Comprehensive market analysis of wearable injectors 2021-2030

by // Leave a Comment

Wearable injectors are small drug delivery systems intended to administer medications continuously for extended periods. They are placed briefly on the skin to quickly and safely administer viscous medications in large quantities via the body’s subcutaneous tissues. Wearable injectors are disposable, user-friendly, and far less painful than commonly used vials and syringes. As a result, they are frequently employed in managing cardiovascular, diabetic, rheumatoid, and cancer disorders.

In 2021, the market value of wearable injectors was worth USD 6.17 billion, and by 2030 it will reach USD 17.75 billion, expanding at a 12.46% CAGR during the forecast period. 

The rising frequency of chronic diseases such as diabetes, cancer, and cardiovascular problems would contribute to the growth of the wearable injector market. The industry is also being driven by a growing number of biological drugs being developed, which are difficult to administer via syringes.

Market Dynamics

Drivers

The factor boosting the market’s growth is the rising prevalence of chronic illnesses such as oncological, neurological, and autoimmune disorders. In addition, the aging population, which is more vulnerable to certain diseases, and the increased demand for minimally invasive (MI) treatment options among patients are boosting the market’s expansion. Injectors that may be used at home and by the user themselves are also becoming more popular since they offer excellent disease management with a low risk of dosage error and needle stick accidents. Further growth-promoting aspects include a number of product developments, such as the incorporation of Bluetooth, wireless communication, and passive warning systems with injectors. 

Furthermore, the market may be constrain by rising demand for alternative drug delivery methods and unfavorable reimbursement arrangements.

Opportunity 

The different approaches used by the major market players to introduce cutting-edge products will boost market expansion during the forecast period. For instance, in February 2021, Subcuject, a global innovator of proprietary device platforms, and Phillips-Medisize collaborated to commercialize a revolutionary wearable bolus injector. With such product introductions, the market for wearable injectors will have substantial growth during the forecast period.

Market Segmentation

By Technology

On the basis of type, the wearable injectors market is segment into the rotary pump, spring-based, expanding battery, motor-driven, and others. 

The spring-based segment was the biggest market contributor in 2021, with a revenue share of nearly 35.91%. The largest market share of this segment is because it is user-friendly and allows patients to accurately administer the medication subcutaneously by pressing one or more buttons on the device.

Furthermore, the rotary pump segment will expand at a rapid rate of 15.47% CAGR because they are easier to use than other wearable injectors.

By Application

On the basis of application, the wearable injectors market is segment into cardiovascular diseases, autoimmune diseases, infectious diseases, oncology, and others. 

In 2021, the oncology segment ruled the market with a significant revenue share of nearly 29.94%. It is primarily due to the rising rate of cancer and patients’ increasing tendency to self-administer their medications. Per the Canadian Cancer Society, about 7% of Canadian men will develop lung. And bronchus cancer leading to nearly 5% of deaths. Also, the market will rise due to technical developments. And the availability of wearable injectors for the treatment of these disorders. 

By End-Use

On the basis of end-user, the market is segment into clinics, hospitals, homecare, and others. 

In 2021, the home care segment led the entire market with a revenue share of approximately 41.8%. The largest share of this segment is due to the growing need for home-based healthcare. And the need for advanced drug delivery devices that requires less expertise and fewer hospitalization rate of patients. Additionally, the home care segment is also drive by the low cost of wearable injectors. And the growing desire to reduce healthcare costs.

Regional Analysis 

In 2021, North America was the biggest regional market, with a 15.215 CAGR and revenue of nearly USD 2,212.6 million. The largest market share is due to the expanding rate of chronic disorders and lifestyle-related ailments. And the presence of advanced healthcare infrastructure. Furthermore, the demand for the wearable injector market is drive by the introduction of numerous novel medications that can successfully cure chronic diseases. Also, the growing acceptance of tailored pharmaceuticals may have a favorable effect on the market in the coming years.

Furthermore, Asia Pacific will expand at a rapid rate of 15.58% CAGR. This growth is due to the region’s favorable government initiatives supporting the use of medical devices like wearable injectors. The growing geriatric population, and rising healthcare spending.

Key Players 

  • Johnson & Johnson Services, Inc.
  • Becton, Dickinson, and Company
  • Unilife Corporation
  • Amgen, Inc.
  • Ypsomed
  • Hoffmann-La Roche Ltd.
  • SteadyMed Therapeutics, Inc.
  • Insulet Corporation
  • West Pharmaceutical Services, Inc.
  • Enable Injections
  • CeQur SA

In 2021, the market value of wearable injectors was worth USD 6.17 billion. And by 2030 it will reach USD 17.75 billion, expanding at a 12.46% CAGR during the forecast period. The rising rate of chronic illnesses, expanding senior population. And the increased concern over needle stick injuries are the key factors stimulating market expansion.

Related Reports:

Advanced Driver Assistance Systems Market Report – The global advanced driver assistance systems (ADAS) market will witness a robust CAGR of 13.83%, valued at $23.44 billion in 2021, expected to appreciate and reach $75.23 billion by 2030, confirms Strategic Market Research. ADAS (Advanced Driver Assistance Systems) are technologies and electronic systems in a vehicle to assist the driver.

Comprehensive market research on liquid biopsy for breast cancer

by // Leave a Comment

A breast cancer liquid biopsy is a quick and painless substitute for surgical biopsies that enables doctors to learn many details about a tumor from just one blood sample. Moreover, liquid biopsy for breast cancer patients may enhance treatment and clinical results. Due to advances in technology and medicinal therapy, liquid biopsy for breast cancer is very fragmented.

In 2021, the market value of breast cancer liquid biopsy was worth USD 124.46 million, and by 2030 it will reach USD 604.71 million, growing at a 19.2% CAGR during the forecast period. 

The market is driven by factors like the rising incidence of breast cancer cases, rising demand for minimally invasive procedures, rising cancer awareness, rising healthcare costs, and initiatives taken by the government and international health organizations. Moreover, the market will grow due to more intensive cancer research and development, technology developments, and a rise in demand for individualized therapy.

Market Dynamics

Drivers

The primary factor boosting market growth is the increasing rate of breast cancer in the general population. For instance, according to the WHO, in 2020, nearly 2.3 million women were diagnosed with breast cancer causing 685,000 deaths globally. One of the most common applications of liquid biopsy is a breast cancer diagnosis, which employs mutational analysis to select the most effective targeted treatment. For instance, determining the next stage of treatment for patients with metastatic sickness can be assisted by screening for the PIK3CA mutation, which is present in about 40% of all HR-positive breast tumors.

Increased initiatives from major market players will fuel expansion over the forecast period. Several businesses are launching steps to expand the use of biopsies globally, which is accelerating growth.

Restraints

The development of the market is severely constrained by the lack of accessibility to and awareness of breast cancer in developing nations. Also, there is a shortage of qualified doctors, and late-stage diagnosis occurs occasionally.

Opportunity 

Due to technological developments in the field of ongoing research on circulating biomarkers, a less intrusive way of diagnosing non-hematological tumors has been create. A growing number of people are becoming aware of the clinical significance of liquid biopsy due to ongoing developments in related fields. Further interventional clinical trials are require, combine with the creation of an algorithm to combine the right circulating biomarkers to make these technologies widely accessible. The commercialization of such tests in the following years will simplify the detection of the ailment. According to John Hopkins Medical in June 2022, liquid biopsy can detect advanced breast cancer biomarkers in 5 hours.

Market Segmentation

By Circulating Biomarkers

In 2021, the circulating cell-free DNA (cfDNA) segment ruled the entire market. It is due to the ability of cfDNA to diagnose recurrence or progression, detect growing genomic anomalies linked to drug resistance, and track tumor molecular profiles in real time.

The circulating tumor cell will expand rapidly during the forecast period. It is due to the capacity of CTCs to provide increased sensitivity as biomarkers for early cancer diagnosis. With larger CTCs counts attributed to a very high risk of getting cancer.

By Application

In 2021, the treatment selection segment was the market leader. With a significant revenue share due to the requirement for early treatment. The relevance of early identification, characterization. And management of breast cancer in its early stages has increased due to the development of liquid biopsies to improve. The likelihood of effective therapy selection and improved prognosis.

Regional Analysis

North America was the biggest regional market in 2021. This is due to rapid technological development, the use of liquid biopsies in treatment decision-making, and expanding government initiatives. Due to higher investments and numerous biotechnology businesses developing the test, the U.S. dominates the North American market.

Over the forecast period, Asia Pacific will see profitable growth. It is due to the expanding population, the growing need for services, and the emergence of major market players. There is a larger population base and a growing cancer rate in the Asia Pacific region. According to Global Cancer Statistics 2020, Asia Pacific was home to nearly 58.3% of cancer deaths. And approximately half of all cancer incidences in 2020.

Key Players 

  • Qiagen
  • Guardant Health Inc.
  • Biocept Inc
  • Hoffmann-La Roche Ltd
  • Janssen Diagnostics
  • Myriad Genetics
  • Johnson & Johnson 
  • Biodesix
  • Fluxion Biosciences Inc.
  • Illumina Inc.
  • Adaptive Biotechnologies

In 2021, the market value of breast cancer liquid biopsy was worth USD 124.46 million. And by 2030 it will reach USD 604.71 million, growing at a 19.2% CAGR during the forecast period. The market growth is accelerate by the increasing rate of breast cancer. Increased awareness of early diagnosis and treatment, and a greater desire for non-invasive procedures.

Related Reports:

Green Hydrogen Market Report – The global green hydrogen market will witness a robust CAGR of 55.1%, valued at $1.45 billion in 2021, expected to appreciate and reach $75.72 billion by 2030, confirms Strategic Market Research. Europe had the highest share of the worldwide green hydrogen market, with more than 57%.

Market research and developments for neurostimulation devices

by // Leave a Comment

The use of low-voltage electricity to impact neuronal transmission at a specific nerve or target in the spinal cord or brain is known as neurostimulation. It is a therapeutic tool used for various conditions, including epilepsy, migraine, Parkinson’s disease, and neuropathic pain, or to modify motor function. The growing frequency of neurological illnesses and the rising elderly population contribute to the enormous growth of the global market for neurostimulation devices.

In 2021, the market for Neurostimulation devices was worth USD 4.796 billion, and by 2030 it will reach USD 50.7 billion, expanding at a 12.8% CAGR during the forecast period. 

The rising prevalence of neurological illnesses like Parkinson’s disease, epilepsy, depression, chronic pain, etc., is a major driver of the market for neurostimulation devices. In the coming years, the market for neurostimulation devices will grow due to rising R&D efforts to create technologically sophisticated devices and rising trends for minimally invasive operations, drug-free treatments, and therapeutic potential.

Market Dynamics

Drivers

Major factor stimulating the growth of the market is the rise in neurological and lifestyle-related illnesses and the world’s rapidly expanding elderly population. Also, patients’ growing desire for minimally invasive (MI) operations is bolstering the market’s expansion. For instance, deep brain stimulation (DBS) is a MI technique that sends electrical signals to a particular location in the brain circuits using neurostimulation devices. This helps in the treatment of several degenerative diseases, including Parkinson’s and Alzheimer’s. In the next years, the market will be driven by factors such as the medical industry’s rapid expansion, rising healthcare costs, and intensive research and development (R&D) efforts.

 Restraints

However, unfavorable elements like rising device costs, the expanding availability of alternative treatment methods. And unfavorable side effects and hazards connected to neurostimulation devices, such as allergic reactions. And skin prickling, are expected to impede market revenue growth.

Opportunities

Modern products and technologies have been develop in response to the unmet needs of patients. And surgeons to improve production efficiency and outcomes. To improve the overall health of patients suffering from neurological disorders and provide improved & creative treatments to meet medical needs, businesses have developed novel products and technology, such as neurostimulation devices.

Market Segmentation

Product Insights

On the basis of product, the market is segment into vagus nerve, deep brain, spinal cord stimulator, sacral nerve, and gastric electric stimulators.

The spinal cord stimulator led the entire market in 2021, accounting for a revenue share of more than 51.5%. It is due to a wide range of product applications and a sizable market penetration of commercially available products. The market segment will grow due to the technical developments in this field. Spinal cord stimulators used to treat non-malignant chronic neuropathic pain produce minute nerve impulses without causing any physical changes to the target region.

Application Insights

On the basis of application, the Neurostimulation devices market is segmented into epilepsy, pain management, essential tremors, depression, urinary & fecal incontinence, dystonia, Parkinson’s disease, gastroparesis, and others. 

With a revenue share of more than 68.0%, the pain management segment ruled the entire market in 2021. The expansion of this market is drive by the rising incidence of chronic pain issues. And an increase in product usage for pain management due to its high therapeutic value. The conditions mentioned in this section are leg pain, disc surgery discomfort, and chronic pain.

Regional Analysis 

North America was the biggest market contributor, with 60% of the revenue share. The main factors driving the neurovascular devices market in North America are the problem with critical sickness. The growth of minimally intrusive nervous system scientific techniques, and the continued expansion of injury/crisis care offices in the US. 

Asia Pacific will experience the quickest regional market growth during the forecast period. Numerous international businesses are moving their manufacturing bases to this region. Due to the availability of unmet medical demands and untapped growth potential. The rapid economic development of emerging nations like China and India. And rising healthcare costs will support market expansion in the APAC region.

Key Players 

  • Neutronics Inc.
  • Nevro Corp.
  • Jude Medical, Inc.
  • Boston Scientific Corp.
  • EndoStim Inc.
  • Cyberonics
  • ElectroCore Inc
  • NeuroPace Inc.
  • Medtronic PLC
  • Aleva Therapeutics SA
  • NeuroSigma, Inc.
  • Synapse Biomedical Inc.
  • On February 2023, SenTiva DUO, a new implantable pulse generator, was introduce by the medical technology company LivaNova (IPG). The new IPG, which has a dual-pin head, is intend to deliver Vagus Nerve Stimulation (VNS) therapy for treating drug-resistant epilepsy.

In 2021, the market for Neurostimulation devices was worth USD 4.796 billion. And by 2030 it will reach USD 50.7 billion, expanding at a 12.8% CAGR during the forecast period. Growing geriatric populations, the introduction of technologically advanced products and the rising rate of chronic disorders like migraine. And epilepsy are some of the major factors boosting the market growth.

Related Reports:

Immunoassay Market Report – The global immunoassay market will witness a robust CAGR of 7.3%, valued at $24.30 billion in 2021, expected to appreciate and reach $45.82 billion by 2030, confirms Strategic Market Research. North America is poise to lead the industry, followed by Europe. Pathogens, such as bacteria, fungus, protozoa, worms, viruses, and prions, cause infectious diseases.